The evolving need for patient reported outcome data in determining choice of immune therapy treatment

Abstract

Cellular therapy has changed the cancer treatment landscape and potential associated toxicities. The traditional short-term toxicities of chemotherapy-induced nausea, vomiting, and diarrhea are replaced by complex immune activation syndromes and immunologic organ-specific toxicities. Understanding the long-term consequences and impact of these therapies on patient quality of life is necessary.